Advertisement

Topics

Mateon Therapeutics Announces Positive Initial Data From Fifth Cohort Of Phase Ib Study Of Oxi4503 In Relapsed/Refractory AML

20:00 EDT 30 Jul 2017 | BioSpace

  Life Sciences Jobs   ...

Original Article: Mateon Therapeutics Announces Positive Initial Data From Fifth Cohort Of Phase Ib Study Of Oxi4503 In Relapsed/Refractory AML

NEXT ARTICLE

More From BioPortfolio on "Mateon Therapeutics Announces Positive Initial Data From Fifth Cohort Of Phase Ib Study Of Oxi4503 In Relapsed/Refractory AML"

Quick Search
Advertisement